SCHEMBL29378308

SCHEMBL29378308

Clc1ncnc2[nH]cc(-c3ccccc3)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 9/20 0.61
PRKACA P17612 6/20 0.58
GSK3B P49841 6/20 0.58
GSK3A P49840 5/20 0.58
CDK5 Q00535 5/20 0.58
ROCK1 Q13464 5/20 0.58
DYRK1A Q13627 5/20 0.58
MAP4K4 O95819 5/20 0.58
PRKD3 O94806 4/20 0.58
CLK2 P49760 4/20 0.58
MAP4K2 Q12851 4/20 0.58
NTRK1 P04629 4/20 0.58
CLK4 Q9HAZ1 4/20 0.58
TAOK1 Q7L7X3 3/20 0.58
NTRK2 Q16620 3/20 0.58
NTRK3 Q16288 3/20 0.58
PAK4 O96013 3/20 0.58
CDK8 P49336 2/20 0.58
MAP2K1 Q02750 2/20 0.58
CAMK2A Q9UQM7 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3226104 1.00 LRRK2 (0.61) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL19533502 0.88 LRRK2 (0.52) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL7060408 0.84 STK3 (0.56) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL16636871 0.82 LRRK2 (0.61) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL7021288 0.81 LRRK2 (0.63) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL15032863 0.81 JAK3 (0.68) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL2257351 0.80 MAPT (0.56) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL2253936 0.80 CHEK1 (0.46) LRRK2PRKACAGSK3BGSK3ACDK5
SCHEMBL30372928 0.80 LRRK2 (0.59) LRRK2STK3CHEK1JAK3JAK2
SCHEMBL15401054 0.79 LRRK2 (0.70) LRRK2STK3STK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250276-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE MITOKININ, INC. (US) 2025-08-07 US disclosed
CN-112585147-B MAP4K4 inhibitors 帝国理工学院创新有限公司 2023-12-05 CN disclosed
CN-112236430-B Cyclopyrazolone formamide compound and preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-02-17 CN disclosed
EP-3947390-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE Mitokinin, Inc. (US) 2022-02-09 EP disclosed
CN-114026093-A Compositions for treating neurodegenerative and mitochondrial diseases and methods of use thereof 麦托吉宁公司 2022-02-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250276-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE PINK1, NLN, NME4 LRRK2 171/4885PRKACA 1244/4885GSK3B 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.